THE J DAVID GLADSTONE INSTITUTES

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1972

Legal Domicile

Principal Officer

ROBERT OBANA

Phone

4157342000

Tax Period

2023-01-01 to 2023-12-31

THE J DAVID GLADSTONE INSTITUTES, founded in 1972, is a major nonprofit in the Medical Research sector that reported $119.2M in total revenue in fiscal year 2023. Revenue decreased 18% compared to the prior year.

Mission

TO DRIVE A NEW ERA OF DISCOVERY IN DISEASE ORIENTED SCIENCE AND TO MENTOR TOMORROW'S LEADERS IN AN INSPIRING AND DIVERSE ENVIRONMENT.

Program Service Accomplishments

Program 1

Expenses: $38,145,444 Revenue: $34,858,161

THE INSTITUTE OF NEUROLOGICAL DISEASE MAINTAINS A STRONG FOCUS ON NEURODEGENERATIVE AND NEUROINFLAMMATORY DISEASES, INCLUDING ALZHEIMER'S DISEASE AND OTHER DEMENTIAS, PARKINSON'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS (ALS), AND MULTIPLE SCLEROSIS. THE INVESTIGATORS ARE SEARCHING FOR COMMON THREADS THAT WILL ALLOW THEM TO IDENTIFY THERAPEUTIC INTERVENTIONS THAT MIGHT BENEFIT MULTIPLE CONDITIONS. THEY ARE USING UNCONVENTIONAL APPROACHES TO IDENTIFY SUCH MULTI-FACETED SOLUTIONS, WHILE ALSO LEVERAGING CAPABILITIES IN REGENERATIVE AND PERSONALIZED MEDICINE.

Program 2

Expenses: $20,134,151 Revenue: $20,465,969

THE INSTITUTE OF VIROLOGY HAS MADE SIGNIFICANT CONTRIBUTIONS TO FIGHT HIV/AIDS, SARS-COV-2, HEPATITIS C, ZIKA, AND CYTOMEGALOVIRUS INFECTIONS LEADING TO GLOBAL AND GROUNDBREAKING EFFORTS IN HIV...

THE INSTITUTE OF VIROLOGY HAS MADE SIGNIFICANT CONTRIBUTIONS TO FIGHT HIV/AIDS, SARS-COV-2, HEPATITIS C, ZIKA, AND CYTOMEGALOVIRUS INFECTIONS LEADING TO GLOBAL AND GROUNDBREAKING EFFORTS IN HIV PREVENTION AND CURE. ITS STATE OF THE ART BSL3 LABORATORIES HAVE ALLOWED GLADSTONE TO DO GROUNDBREAKING WORK IN UNDERSTANDING THE COVID-19 VIRUS AND OTHER VIRUS DRIVEN DISEASES. BY FOCUSING ON PREVENTION, DIAGNOSIS, AND THERAPEUTICS, THE INSTITUTE AIMS TO DEVELOP PROACTIVE STRATEGIES TO TACKLE CURRENT AND FUTURE PANDEMICS.

Program 3

Expenses: $17,584,039 Revenue: $11,403,794

THE INSTITUTE OF CARDIOVASCULAR DISEASE LEVERAGES IMPORTANT GENETIC, DEVELOPMENTAL, CHEMICAL, BIOLOGICAL SYSTEMS, COMPUTATIONAL, AND ENGINEERING APPROACHES TO STUDY HEART DISEASE AND STEM CELL...

THE INSTITUTE OF CARDIOVASCULAR DISEASE LEVERAGES IMPORTANT GENETIC, DEVELOPMENTAL, CHEMICAL, BIOLOGICAL SYSTEMS, COMPUTATIONAL, AND ENGINEERING APPROACHES TO STUDY HEART DISEASE AND STEM CELL BIOLOGY.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $20,222,638

Program Service Revenue $85,513,618

Investment Income $12,949,622

Other Revenue $522,648

TOTAL REVENUE $119,208,526

Expense Breakdown

Grants Paid $0

Salaries & Benefits $65,914,250

Fundraising Expenses $2,061,343

Program Expenses $107,172,641

Other Expenses $61,754,782

TOTAL EXPENSES $127,669,032

Year-over-Year Comparison

	2023	2022	Change
Revenue	$119,208,526	$144,774,821	-0.2%
Expenses	$127,669,032	$118,956,646	+0.1%
Net Income	$-8,460,506	$25,818,175	-1.3%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

N/A

Employees

581

Volunteers

126

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$1,994,177

Total Directors

$1,275,000

Key Employees

$4,167,489

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
NICHOLAS J SIMON	TRUSTEE	3.00	Director	$425,000	$0	$425,000
ANDREW S GARB	TRUSTEE	3.00	Director	$425,000	$0	$425,000
WILLIAM PRICE	TRUSTEE	3.00	Director	$425,000	$0	$425,000
DEEPAK SRIVASTAVA	PRESIDENT	40.00	Officer	$1,209,292	$91,079	$1,300,371
ROBERT OBANA	COO	40.00	Officer	$613,776	$80,030	$693,806
WARNER GREENE	DIRECTOR (THRU 12/23)	40.00	Key Emp	$377,315	$80,030	$457,345
LENNART MUCKE	DIRECTOR	40.00	Key Emp	$600,802	$63,851	$664,653
KATHERINE POLLARD	DIRECTOR	40.00	Key Emp	$489,200	$89,333	$578,533
BENOIT BRUNEAU	DIRECTOR	40.00	Key Emp	$506,804	$91,079	$597,883
MELANIE OTT	DIRECTOR	40.00	Key Emp	$534,623	$91,079	$625,702
ALEX MARSON	DIRECTOR	40.00	Key Emp	$530,966	$77,012	$607,978
STEVEN M FINKBEINER	DIRECTOR	40.00	Key Emp	$544,316	$91,079	$635,395
LEOR WEINBERGER	SR. INVESTIGATOR	40.00	Highest	$486,707	$91,079	$577,786
STEPHEN FREEDMAN	VP FOR CORP LIAISON & VENTURES	40.00	Highest	$473,173	$63,851	$537,024
ROBERT WICKS	VP OF PHILANTHROPY	40.00	Highest	$427,001	$56,587	$483,588
JENNIFER CROSBY	VP OF PEOPLE SERVICES	40.00	Highest	$470,611	$74,579	$545,190
MICHELLE SIBLY	VP OF FINANCE	40.00	Highest	$436,597	$49,500	$486,097

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$119,208,526	$127,669,032	$365,291,245	$-8,460,506
2022	$144,774,821	$118,956,646	$358,330,486	$25,818,175
2021	$143,049,979	$103,017,350	$367,466,101	$40,032,629
2020	$84,274,665	$93,512,759	$318,407,379	$-9,238,094
2019	$62,831,350	$82,269,244	$314,172,354	$-19,437,894
2018	$86,315,298	$83,576,420	$257,431,204	$2,738,878